期刊文献+

小檗碱改善代谢性疾病的肠道相关机制 被引量:5

The gut-related mechanisms of berberine in the treatment of metabolic diseases
原文传递
导出
摘要 小檗碱是中药黄连的主要成分,临床上常用作抗菌药物,近年来研究发现其有显著的降血糖、改善代谢性疾病相关症状的作用,但机制尚未完全明确.研究显示,小檗碱可通过影响肠道功能发挥作用,其可能机制包括调控肠道激素分泌、调整肠道菌群结构、改善肠道能量代谢、减轻低水平慢性炎性反应、保护肠道屏障功能等.通过探讨小檗碱改善代谢作用的肠道相关机制,可为小檗碱的临床应用提供理论参考,并为代谢性疾病的治疗方法开拓新思路。 Berberine, a major constituent of Chinese herb Coptis Chinensis commonly used as antibacterial agents, has recently been demonstrated to be effective in lowering glucose and alleviating symptoms of metabolic diseases. However, the mechanism has not yet been well explained. Recent researches suggest that the intestinal tract may be associated with its effect. The possible mechanisms include modulating gastrointestinal hormones, adjusting the structure of gut microbiota, improving intestinal metabolism, alleviating low-grade inflammation and protecting intestinal barrier. Further clarifying the intestinal-related mechanisms of berberine's improvement on metabolism can provide a theoretical basis for its clinical application and develop new ideas for the treatment of metabolic diseases.
出处 《国际内分泌代谢杂志》 北大核心 2014年第6期386-389,共4页 International Journal of Endocrinology and Metabolism
基金 国家自然科学基金资助项目(81170784) 上海市科委医学引导项目(14411964700)
关键词 小檗碱 2型糖尿病 肠道激素 肠道菌群 Berberine Type 2 diabetes mellitus Gastrointestinal hormones Gut microbiota
  • 相关文献

参考文献2

二级参考文献20

  • 1Fei LI Hua-dong WANG Da-xiang LU Yan-ping WANG Ren-bin QI Yong-mei FU Chu-jie LI.Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice[J].Acta Pharmacologica Sinica,2006,27(9):1199-1205. 被引量:24
  • 2Tang J, Feng Y,Tsao S,et al. Berberine and Coptidis rhizome as novel antineoplastic agents : a review of traditional use and biomedical inves- tigatims [ J ]. J Eihnopharmaco|, 2009 ( 126 ) : 5-17.
  • 3Xic W.Gu I), l,i J,el al. Eftcts and action mechanisnl of Bberberine and Rhizoma coptidis on guI microbes and obesity in high-fat diet-fed C57 B l,/6J mice [ J ]. LOS one, 2011,6 ( 9 ) : e24520.
  • 4Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabe- tes mellitus[ J]. Metabol Clin Exp,2008(57 ) :712-717.
  • 5Han J,Lin H, Huang W. Modulation gut microbiota as an anti-diabetic mechanism of berberine [ J ]. Med Sci Monit, 201 1, 17 ( 7 ) : RA164- 167.
  • 6Zhang X Zhao Y,Zhang M,et al. Structural cilanges of gut microbiota during Berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats [ J ]. PI.oS one, 2012,7 ( 8 ) : ed-2529.
  • 7Gill SR, Pop M, DeBoy RT,et al. Metagenomic analysis of the human distal gut microbiome[ J]. Science,2006(312) :1355-1359.
  • 8Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiota with increased capacity for energy harvest[ J ]. Nature ,2006 ( 444 ) : 1027-1023.
  • 9B? ckhed F, Ding H, Wang T, et al. The gut microbiota as an environ- ment factor that regulates fat storage [ J ]. Proc Natl Acad Sci U S A, 2004,101 (44) :15718-15723.
  • 10Round JL,. Mazmanian SK. The gut microbiota shapes intestinal im- mune responses during health and disease[ J]. Nat Rev lmmunol,2009 (9) :313-323.

共引文献49

同被引文献38

引证文献5

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部